Document is current
Any future updates will be listed below
-
Authors
Escribano-Subias, Pilar
,
López, Raquel
Almenar, Luis
Lázaro, María
Forn, Ian
Torrent, Anna
Blanco, Isabel
Barberà, Joan Albert
-
Funding
Funding for this research was provided by:
Actelion Pharmaceuticals España S.L¸ (Actelion Pharmaceuticals España S.L¸)
-
License Information
Text and Data Mining valid from 2020-06-02
Version of Record valid from 2020-06-02
-
More Information
Article History
Received: 28 August 2019
Accepted: 22 May 2020
First Online: 2 June 2020
Ethics approval and consent to participate
: The protocol was approved by the independent ethics committee at Hospital universitario y politécnico la Fe (e-mail: ExternalRef removed, protocol reference number: ACT-MAC-2015-01) and all patients provided written informed consent before participation.
: Not applicable.
: PE has received has received consulting/speaker fees and advisory board from Actelion Pharmaceuticals España S.L; Bayer, GlaxoSmithKline and Merck Sharp & Dohme, her institution has received grant support from Actelion Pharmaceuticals España S.L; Bayer, GlaxoSmithKline and Ferrer, and has received honoraria for her collaboration in the PRACMA study. RL has received honoraria for her collaboration in the PRACMA study. ML has received honoraria for her collaboration in the PRACMA study, and educational and consulting honoraria from Actelion Pharmaceuticals España S.L. IA and AT were employees of Actelion Pharmaceuticals España S.L. IB has received honoraria for her collaboration in the PRACMA study. JAB has received honoraria for consultation or speaker fees from Actelion and Merck; research support through his institution from Actelion, Merck, GlaxoSmithKline and Ferrer; and has received honoraria for his collaboration in the PRACMA study.
